EMA Panel Backs Lilly’s Oral GLP-1 Foundayo, Opening EU Obesity Race
The CHMP has recommended EU authorization for Lilly’s oral GLP-1 Foundayo (orforglipron) in weight management and type 2 diabetes, with the European Commission set to decide.
The CHMP has recommended EU authorization for Lilly’s oral GLP-1 Foundayo (orforglipron) in weight management and type 2 diabetes, with the European Commission set to decide.